Results 191 to 200 of about 4,970 (234)

Hepatitis Associated with Dantrolene Sodium

Annals of Internal Medicine, 1976
Excerpt Dantrolene sodium, a hydantoin derivative that became commercially available in 1974, has been used to decrease skeletal muscle spasticity in patients with various disorders (1-3).
ROBERT M. OGBURN, ROBERT L. MYERS, GEORGE E. BURDICK   +2 more
openaire   +1 more source

Neuroleptic Malignant Syndrome: Response to Dantrolene Sodium

Annals of Internal Medicine, 1983
Abstract The neuroleptic malignant syndrome is an uncommon and potentially lethal complication of treatment with antipsychotic medication (1).
D C, May, S W, Morris, R M, Stewart, B J, Fenton, F A, Gaffney   +4 more
openaire   +2 more sources

Management of lethal catatonia with dantrolene sodium

Critical Care Medicine, 1991
Lethal catatonia, a life-threatening, febrile neuropsychiatric disorder, was reported before the introduction of modern psychopharmacologic treatment. Kraepelin (1) discussed this disorder as a syndrome that comprises a characteristic cluster of symptoms, such as catalepsy, negativism, posturing ...
E, Van de Kelft, M, De Hert, L, Heytens, H E, Demey, J, Gheuens   +4 more
openaire   +2 more sources

Dantrolene sodium and fatigue of long duration

Muscle & Nerve, 1992
AbstractA long‐lasting imparment of muscular force generation follows fatiguing exercise (fatigue of long duration), the physiological basis of which is not well understood. To investigate the role of reduced calcium release in longlasting fatigue, we examined the effects of dantrolene sodium, which selectively decreases calcium release from the ...
R S, Moussavi, S L, Lehman, R G, Miller
openaire   +2 more sources

Dantrolene Sodium

Drugs, 1977
Dantrolene sodium or dantrolene1 is 1([5-(nitrophenyl)furfurylidend] amino) hydantoin sodium hydrate. It is indicated for use in chronic disorders characterised by skeletal muscle spasticity, such as spinal cord injury, stroke, cerebral palsy and multiple sclerosis.
R M, Pinder, R N, Brogden, T M, Speight, G S, Avery   +3 more
openaire   +2 more sources

ChemInform Abstract: SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF DANTROLENE AND SODIUM DANTROLENE

Chemischer Informationsdienst, 1985
AbstractDer Aldehyd (I) reagiert mit Aminohydantoin (II) zu Dantrolen (III), aus dem mit Natrium‐methylat das Natrium‐Salz (IV) erhalten wird.
A. F. OLEINIK, N. I. ANDREEVA, R. D. SYUBAEV, S. M. GOLOVINA, T. I. VOZYAKOVA   +4 more
openaire   +1 more source

Dantrolene Sodium

2021
openaire   +2 more sources

Phenelzine Overdose Treated With Dantrolene Sodium

JAMA: The Journal of the American Medical Association, 1986
THE INGESTION of a monoamine oxidase (MAO) inhibitor can induce a complex array of hypermetabolic signs, including hyperpyrexia, tachycardia, generalized muscle rigidity, tachypnea, metabolic acidosis, hypoxemia, and hypercapnia 1 (J. W. Katalavis, MD, oral communication, November 1984).
openaire   +1 more source

Dantrolene sodium: urinary metabolites and hepatotoxicity.

Research communications in chemical pathology and pharmacology, 1983
Dantrolene is metabolized by the hepatic MFO system to hydroxydantrolene which is conjugated with glucuronic acid or with sulfate. Dantrolene is also metabolized by nitroreductase to aminodantrolene. The aminodantrolene inhibits the hepatic MFO system.
T H, Arnold, J M, Epps, H R, Cook, M E, Hamrick   +3 more
openaire   +1 more source

Dantrolene Sodium Capsules

2023
openaire   +1 more source